Viome Solaria Bio Acquisition and the Evidence Behind the Bondia 85% Bone Density Claim

October 8, 2026 · Platform news · Gut health

What the Acquisition Includes

The acquisition adds a microbial biobank and two synbiotic formulations to the Viome product catalog under undisclosed financial terms. Viome announced the purchase of Sōlaria Biō on October 1, 2026, through a corporate release distributed by FinancialContent.

Sōlaria Biō develops medical foods using microbial strains isolated from fruits, vegetables, and fermented foods. The target company maintains an isolate library containing more than 5,700 bacterial and fungal strains. Sōlaria Biō processes these isolates through machine-learning models designed to predict strain function.

The transaction transfers three assets to Viome:

• Bōndia: A bone-health synbiotic and medical food evaluated clinically under the candidate name SBD111.
• SBD121: A microbial synbiotic currently in research and development for joint health.
• An isolate biobank: More than 5,700 bacterial and fungal isolates.

Commercial Availability and Product Distribution

The release states that Bōndia is available on solaria.bio. The product will expand distribution to viome.com later in 2026.

The most notable structural shift for consumers is product access. Bōndia represents Viome's first product available without requiring a Viome test.

What the Trial Behind the 85% Actually Found

The randomized controlled trial evaluating Bōndia missed its primary endpoint across the full study population. Clinical researchers evaluated the formula as SBD111 under registration NCT05009875. The complete results were published in Osteoporosis International by Schott and colleagues in October 2025, with companion indexing on PubMed Central.

The clinical trial enrolled 286 women who were 1 to 6 years post-menopause across two clinical sites located in Brisbane and Sydney, Australia. Enrollment ran from November 2021 to July 2023. A total of 221 participants completed the 12-month randomized, double-blind, placebo-controlled study, representing a 77% completion rate.

For the primary outcome of lumbar-spine bone mineral density (BMD) loss at 12 months, the SBD111 group demonstrated a 0.15% reduction in loss compared to placebo. The 95% confidence interval (CI) ranged from −0.52% to 0.82%. This outcome was not statistically significant. In the paper, the authors report that SBD111 did not significantly reduce bone-density loss for the full cohort.

Subgroup Outcomes in the Clinical Record

The marketing materials emphasize prespecified and post hoc subgroups rather than the primary trial outcome. In a prespecified subgroup of women with osteopenia, researchers reported a 0.89% absolute difference in femoral neck BMD favoring the intervention. The 95% confidence interval for this difference spanned from −0.277% to 2.051%. This subgroup contained 83 participants, with 43 assigned to SBD111 and 40 assigned to placebo.

Because that confidence interval crosses zero into negative territory, the subgroup finding is not statistically significant. The numerical data remain compatible with no clinical effect. This 0.89 percentage point difference serves as the baseline for the headline marketing claim. Sōlaria Biō's own home page states that Bōndia "improved bone density outcomes by 85%" in women with osteopenia, checked on October 8, 2026.

A separate prespecified subgroup examined participants with a body mass index (BMI) of 30 or greater. In this group of 42 women (26 receiving SBD111 and 16 receiving placebo), total hip BMD showed a 0.97% absolute difference, with a 95% confidence interval of 0.015% to 1.925%. Because this interval excludes zero, it achieved statistical significance. Researchers observed a concurrent secondary reduction in serum cross-linked C-telopeptide of type I collagen (CTX-1), which is a circulating biomarker of bone resorption. A separate claim regarding elevated body fat was evaluated post hoc rather than prespecified.

The journal publication included a detailed financial conflict disclosure. Authors R.S.G., D.D.M., E.M.S., M.R.C., A.E.B., and G.V.T. are employees of and share equity in Sōlaria Biō, Inc.

How a 0.89-Point Difference Becomes 85%

A relative reduction of 85% compares two small baseline loss rates. It does not describe a large gain in bone mass.

Over 12 months, postmenopausal women naturally lose bone mineral density. The 84.5% or 85% relative figure is computed from the 0.89 percentage point absolute difference.

Relative statistics amplify small numerical separations. An 85% relative improvement sounds as though bone density surged, yet the physical difference between the study groups was less than one percent of bone mass. Furthermore, when the 95% confidence interval ranges from −0.277% to 2.051%, the true population difference could be zero or even favor the placebo arm. The separate 73.7% relative figure promoted for individuals with a BMI of 30 or greater stems from an absolute difference of 0.97 percentage points in a cohort of 42 participants. Our methodology requires evaluating absolute risk reductions alongside relative claims to prevent distorted interpretations.

What Changes for an Existing Viome Customer

The acquisition introduces Viome's first product that does not require a Viome test. Previously, Viome products required a test, as detailed in our Viome review.

Selling a synbiotic off the shelf changes who Viome can sell to, because the test is no longer the entry point.

For existing subscribers, the transaction changes very little about current services:

• Core testing protocols: Viome's gut panel itself remains unchanged.
• Supplement recommendations: Existing test-based recommendations remain unchanged.
• Platform comparisons: The operational distinctions we analyzed in our Viome vs Zoe comparison continue to apply to Viome's core diagnostic line.
• Diagnostic directory: The criteria outlined in our best gut health test guide remain the standard for evaluating Viome's testing.

What the Trial Did Not Measure

Nothing in the trial speaks to fracture prevention. The SBD111 trial did not measure fractures as an outcome. Bone density measurements do not establish fracture protection.

What Is Not Published

A review of the solaria.bio home page conducted on October 8, 2026, confirmed that no price appears on the front page. The page shows SHOP NOW and Shop Bōndia links alongside a subscriber login button, requiring prospective customers to click through from solaria.bio to an internal sales screen to view pricing figures. Because no figure is published on the page we checked, this briefing states no price for Bōndia.

Corporate financial terms also remain undisclosed. The press announcement omits the acquisition price and deal terms.

Fracture outcome data are absent as well. NCT05009875 concluded after 12 months, and bone density was the measure throughout.

What Would Change This Read

A definitive clinical assessment of Bōndia would require a fully powered trial measuring confirmed fracture outcomes in a dedicated osteopenia cohort. Three specific developments would alter our editorial evaluation:

• A statistically significant primary endpoint: A trial where bone mineral density preservation in osteopenic individuals serves as the primary outcome, achieving a confidence interval that excludes zero.
• Fracture incidence data: Clinical trial tracking demonstrating fracture outcomes.
• Independent clinical replication: Independent replication without author equity or employment in the sponsor.

Sources

• Viome, "Viome Acquires Sōlaria Biō to Launch Clinically Validated Consumer Synbiotics and Medical Foods," company release distributed via Business Wire, October 1, 2026, full text at financialcontent.com (accessed October 8, 2026). Source of the acquisition date, the undisclosed terms, the description of Sōlaria Biō, the biobank of more than 5,700 bacterial and fungal isolates, Bōndia and its clinical name SBD111, SBD121 for joint health, the statement that Bōndia is Viome's first product available without requiring a Viome test, the availability wording for solaria.bio and viome.com, and the named executives.
• Rebecca S. Schott et al., "A synbiotic reduces bone mineral density loss in post-menopausal women: a randomized, double-blind, placebo-controlled trial of SBD111," Osteoporosis International, October 2025, pp. 2019–2030, DOI 10.1007/s00198-025-07650-7 (accessed October 8, 2026). Source of the 286 enrolled and 221 completed, the population of women 1 to 6 years post-menopause, the Brisbane and Sydney sites, the November 2021 to July 2023 enrollment, the 12-month randomized double-blind placebo-controlled design, and the primary lumbar-spine result of 0.15% with its 95% confidence interval of −0.52% to 0.82% together with the authors' statement that SBD111 did not significantly reduce bone-density loss for the full cohort.
• Companion record on PubMed Central (accessed October 8, 2026). Source of the subgroup sizes (43 against 40 in the osteopenia subgroup; 26 against 16 in the BMI 30-or-greater subgroup), the 0.89% femoral-neck difference with its interval of −0.277% to 2.051%, the 0.97% total-hip difference with its interval of 0.015% to 1.925%, the prespecified versus post hoc designations, the serum CTX-1 signal, and the author employment and equity disclosure.
• Trial registration NCT05009875 on ClinicalTrials.gov (accessed October 8, 2026). Source of the registration identifier and the 12-month study duration.
• solaria.bio home page (checked October 8, 2026). Source of the "improved bone density outcomes by 85%" marketing claim and of the finding that no price for Bōndia is published on that page.
• Nutrition Insight and Fitt Insider, trade coverage of the acquisition (accessed October 8, 2026). Used to confirm the event was reported independently of the company release; no figure on this page is taken from either.